Diindolylmethane
Diindolylmethane (DIM) is a phytochemical formed from indole-3-carbinol (I3C) when cruciferous vegetables (broccoli, kale, cabbage, Brussels sprouts) are chewed and digested. I3C dimerizes in the acidic stomach environment to form DIM, which is the more bioavailable and stable active metabolite. While DIM occurs naturally in cruciferous vegetables, achieving therapeutic doses through diet alone requires impractical quantities (~2lb of broccoli daily for 100mg DIM).
Starting dose. 100-200mg — Microencapsulated DIM
Take with a meal containing fat for best absorption (DIM is fat-soluble). Start with 100mg/day to assess tolerance, titrate up to 200-300mg over 1-2 weeks. Monitor estradiol levels every 6-8 weeks if on TRT to avoid over-suppression.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
DIM induces cytochrome P450 1A1 (CYP1A1), the enzyme that hydroxylates estrogens at the 2-position to form 2-hydroxyestrone (2-OHE1) and 2-hydroxyestradiol. This shifts metabolism away from the 16-alpha-hydroxylation pathway (forms 16-alpha-hydroxyestrone, a more proliferative metabolite associated with cancer risk).
The 2-hydroxyestrogens are weaker estrogen receptor agonists, more easily methylated and excreted, and may have anti-proliferative effects. Increased 2:16 ratio is associated with reduced breast cancer risk in observational studies.
DIM modulates androgen receptor activity - has weak antagonist activity at androgen receptors in some tissues (relevant for prostate). It does NOT block testosterone systemically but may modify androgen signaling locally.
DIM activates the aryl hydrocarbon receptor (AhR), which has multiple downstream effects including induction of phase I and phase II detoxification enzymes (UGTs, GSTs, sulfotransferases). This supports general xenobiotic and estrogen clearance.
Anti-proliferative effects: DIM has been shown to induce apoptosis in cancer cell lines (breast, prostate, cervical) via cell cycle arrest, NF-kB inhibition, and modulation of survival signaling. Clinical relevance for cancer prevention/treatment is still being studied.
Aromatase: DIM is NOT a strong aromatase inhibitor at typical supplement doses. Its estrogen-management effects are post-aromatization (metabolite shifting) rather than blocking estrogen production.
Week 1-2: Initial metabolite shift, possible mild side effects (headache, urine color).
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Single absorption-enhanced BR-DIM doses of 100, 150, and 200 mg were administered to healthy adults.
The doses administered were 50, 100, 150, 200, and 300 mg, with the 300-mg dose repeated in an additional group.
Evidence scope. Human single-dose PK study; does not establish repeated once- or twice-daily dosing with meals.
Healthy BRCA carriers took oral DIM 100 mg once daily for one year.
Participants were 23 healthy female BRCA carriers (median age 47 years; 78% postmenopausal) who were treated with oral DIM 100 mg × 1/day for 1 year.
Evidence scope. Human prospective trial; abstract does not identify the product as microencapsulated BR-DIM.
DIM increased the urinary 2-hydroxyestrone to 16-alpha-hydroxyestrone ratio in thyroid proliferative disease.
There was an increase in the ratio of 2-hydroxyestrones (C-2) to 16α-hydroxyestrone (C-16), consistent with antiestrogenic activity that results in more of C-2 product compared with C-16.
Evidence scope. Small Phase I trial at 300 mg/day; supports estrogen-metabolite shifting, not the full page mechanism.
No BR-DIM-related adverse effects were reported through 200 mg.
No BR-DIM-related adverse effects were reported at doses up to 200 mg.
Evidence scope. Single-dose healthy-nonsmoker study; does not establish chronic safety at 1-2 doses daily.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Exact quick-start regimen: 100-200 mg microencapsulated DIM orally 1-2x daily with meals. One abstract supports absorption-enhanced BR-DIM at the amount but only as a single dose; another supports 100 mg oral daily but does not specify microencapsulation.
Primary repeated-use safety: headache, GI upset, estradiol over-suppression, and CYP1A2 interaction. Exact-formulation evidence is single-dose only. Embedded PMID 28069684 resolves to an unrelated Women’s Health Initiative paper.
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
Plasma for DIM metabolites.
Oral with food (BioResponse form).
Plasma clearance 24-48 hours; tissue effects on estrogen metabolism build over weeks.
Plain DIM: ~1-5%. BioResponse DIM (microencapsulated): ~5-10x higher (~10-50% relative). Food (especially fat) significantly improves both forms.
Acute CYP1A1 induction: 12-24 hours. Chronic estrogen metabolism shift: 4-12 weeks of consistent dosing.
Hepatic Phase I (CYP) and Phase II (glucuronidation) metabolism. Biliary and renal excretion of metabolites.
Storage. Store at room temperature (20-25C) in a cool, dry place. Protect from light. Capsules shelf-stable 2+ years.
Classified as a dietary supplement in the US - no prescription required. Widely available. No FDA-approved medical indication.
Put it to work
Open DIM (Diindolylmethane) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open DIM (Diindolylmethane) in the app →Go deeper
The complete DIM (Diindolylmethane) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.